Radspherin[®] shows favorable safety profile in the first interim safety readout from the ongoing randomized phase 2 trial in ovarian cancer
Oslo, Norway, 17 November 2026: Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that no serious adverse event was related to Radspherin® in the interim safety analysis of its ongoing randomized Phase 2 trial (RAD-18-003, NCT06504147) in patients with peritoneal metastases from advanced ovarian cancer. These are the first randomized, controlled safety data for Radspherin®.
As of the data cut-off on 30 October 2026, 74 patients had been randomized (2:1 – Radspherin® : Control). The safety analysis set comprised 56 primary ovarian cancer patients who achieved complete surgical resection after neoadjuvant chemotherapy, of whom 40 received a single intraperitoneal dose of Radspherin® (7 MBq) after surgery in addition to standard of care, and 16 received standard of care alone.
At this stage in the trial, there were no serious adverse events considered related to Radspherin®, no deaths, and no adverse events leading to discontinuation. The proportion of patients with treatment-emergent adverse events (TEAEs, events reported on or after treatment start, regardless of cause) was similar in both arms. The safety profile of Radspherin® remains consistent with previously published clinical data.
The majority of TEAEs in the experimental arm were considered unrelated to Radspherin® and were consistent with the underlying disease and expected postoperative clinical course. At the patient level, the most frequent TEAEs in the experimental arm were constipation, anemia, abdominal pain, nausea and hypokalemia. A total of 10 events reported in five patients (12.5%) were considered as possibly related to Radspherin®. These latter events were all mild or moderate (Grade 1 or 2) and included vomiting (2), nausea, abdominal pain, constipation, headache, dizziness, fatigue, anemia, and decreased lymphocyte count (one event each).
The trial's Independent Data Monitoring Committee reviewed the unblinded safety data on 13 November 2026 and recommended that the trial continue without modification.
"Women in this trial have just been through neoadjuvant chemotherapy and major abdominal surgery, so any treatment added afterwards must be well tolerated," said Professor Ignace Vergote, gynaecologic oncologist and Professor Emeritus at the Catholic University Leuven, Belgium. “It is encouraging to now see this in randomized data. The adverse events observed in both arms of the trial are what we would expect in patients recovering from this type of surgery, which is reassuring for patients and their physicians.”
These randomized data are consistent with the safety profile seen in previous Radspherin® trials: the safety run-in cohort of this trial, completed in March 2025, the Phase 1 trial in recurrent ovarian cancer (RAD-18-001, n=21) and the Phase 1/2a trial in colorectal cancer (RAD-18-002, n=47), in which no dose-limiting toxicity was observed at the recommended dose of 7 MBq [1,2].
“These first randomized data are an important milestone for Oncoinvent and for the Radspherin® program,” said Dr Zuzana Jirakova Trnkova, Chief Medical Officer of Oncoinvent. “The safety profile is in line with what we have reported in previous studies, which strengthens our confidence as we move towards the efficacy readout in the spring and readiness for Phase 3. We thank the patients, investigators and site teams who made this possible."
Recruitment in the phase 2 trial is expected to complete in the first half of 2027. The interim efficacy readout, planned for April 2027, will include close to all randomized patients, of whom approximately 40 will have at least nine months of follow-up.
***
Notes on Safety Terminology
- Adverse event: An unintended medical event reported by a patient during the trial, regardless of whether it is related to the trial drug.
- Treatment-emergent adverse events: Any unintended medical event that began or worsened after the patient received the first dose of the trial drug, whether or not it was caused by the drug.
- Serious treatment-emergent adverse events: A major medical event (such as hospitalization or a life-threatening condition) that began or worsened after treatment started, regardless of whether it was linked to the trial drug.
***
[1] Wang, Yun, et al. "First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer." Gynecologic Oncology 204 (2026): 158-164.
[2] Larsen, Stein Gunnar, et al. "First experience with 224Radium-labeled microparticles (Radspherin®) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study)." Frontiers in medicine 10 (2023): 1070362.
